Boudewijn van Vliet
Director/Board Member at PRYME N.V.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Henning Eskild Jensen | M | 63 | 3 years | |
Michael Pepper | M | - |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | - |
Roberto Speck | M | - |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | - |
John Tchelingerian | M | - |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | 1 years |
Christopher Hervé | M | 41 | 2 years | |
Wim van den Broeck | M | - | 4 years | |
Willem Michiel Kool | M | 64 | 3 years | |
Frans Vollering | M | 58 | 1 years | |
Dominique Gemoets | M | - | 1 years | |
Jan-Willem Muller | M | 47 | 2 years | |
Caroline Lievens | F | - | - | |
Sander Schiereck | M | - | - | |
Marco Alessandrini | M | - |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | - |
Daniel Hunt | M | - |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Johannes D. van der Endt | M | - | 14 years | |
Stephan Anzenhofer | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
Netherlands | 11 | 68.75% |
Switzerland | 5 | 31.25% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Boudewijn van Vliet
- Personal Network